CompletedNCT01106430
Lisdexamfetamine or atomoxetine for children and teens with ADHD after methylphenidate
About this title
Read the official source — NCT01106430Medication studyAges 6–17Multiple countries
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- Dothan and 63 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 28, 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 267
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01106430
- Official title
Show the full official title
A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel Group Study to Assess the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Little Rock, United States · Colton, United States
61 more locations
- San Diego, United States
- Wildomar, United States
- Gainesville, United States
- Hialeah, United States
- Lauderhill, United States
- Orlando, United States
- Roswell, United States
- Libertyville, United States
- Naperville, United States
- Terre Haute, United States
- Wichita, United States
- Paducah, United States
- New Orleans, United States
- Rockville, United States
- Rochester Hills, United States
- Saint Charles, United States
- Lincoln, United States
- Las Vegas, United States
- Toms River, United States
- Staten Island, United States
- Durham, United States
- Fargo, United States
- Oklahoma City, United States
- Gresham, United States
- Philadelphia, United States
- Austin, United States
- Houston, United States
- Lubbock, United States
- San Antonio, United States
- Salt Lake City, United States
- Kirkland, United States
- Hoboken, Belgium
- Leuven, Belgium
- Edmonton, Canada
- Hamilton, Canada
- Oakville, Canada
- Whitby, Canada
- Saskatoon, Canada
- Freiburg im Breisgau, Germany
- Mannheim, Germany
- Bamberg, Germany
- Würzburg, Germany
- Frankfurt (Oder), Germany
- Hagen, Germany
- Szeged, Hungary
- Budapest, Hungary
- Gyula, Hungary
- Pécs, Hungary
- Cagliari, Italy
- Bydgoszcz, Poland
- Warsaw, Poland
- Palma de Mallorca, Spain
- Esplugues de Llobregat, Spain
- Torremolinos, Spain
- San Cristóbal de La Laguna, Spain
- Badajoz, Spain
- Barcelona, Spain
- Gothenburg, Sweden
- Stockholm, Sweden
- Basildon, United Kingdom
- Dundee, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride.
Who was this study for?
Listed age limits: 6 years to 17 years.
